Beijing To Invest RMB 200 Million Annually To Research 10 Major Diseases
This article was originally published in PharmAsia News
The Chinese government will launch a major research project over the next few years, spending RMB 200 million to study 10 severe diseases
You may also be interested in...
Merck & Co.'s vericiguat, an sGC stimulator, was approved for heart failure but it enters a competitive space with a narrow indication.
A top executive at the Swedish company spoke with Medtech Insight about how the mobility and data reliability of 5G cellular technology will change how medtech manufacturers design their products.
Roche's Actemra is a major player in this space, but Humanigen is looking to take it on directly.